CTIS2023-506082-60-00进行中（未招募）1 期
I8F-MC-GPIG - Tirzepatide Study of Renal Function in People with Overweight or Obesity and Chronic Kidney Disease with or without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease using Multiparametric Magnetic Resonance Imaging (TREASURE-CKD) - I8F-MC-GPIG
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Have obesity or overweight, Have chronic kidney disease, Half of participants must have type 2 diabetes and half of participants must not have type 2 diabetes
排除标准
- •Have a history of diabetic eye diseases, Have gained weight within 90 days before study, Have a history of unstable or severe kidney disease
研究者
相似试验
进行中（未招募）
1 期
Tirzepatide Mechanism of Action Study on Renal Function (TREASURE-CKD)EUCTR2021-005273-47-NLEli Lilly and Company140
进行中（未招募）
1 期
Tirzepatide Mechanism of Action Study on Renal Function (TREASURE-CKD)Obesity and Chronic Kidney diseaseMedDRA version: 20.0Level: SOCClassification code 10038359Term: Renal and urinary disordersSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.0Level: SOCClassification code 10027433Term: Metabolism and nutrition disordersSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2021-005273-47-DKEli Lilly and Company140
招募中
2 期
Tirzepatide Study of Renal Function in People with Overweight or Obesity and Chronic Kidney Disease with or without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease using Multiparametric Magnetic Resonance Imaging (TREASURE-CKD)NL-OMON51386Eli Lilly16
进行中（未招募）
1 期
Tirzepatide Mechanism of Action Study on Renal Function (TREASURE-CKD)Obesity and Chronic Kidney diseaseMedDRA version: 20.0Level: SOCClassification code 10038359Term: Renal and urinary disordersSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.0Level: SOCClassification code 10027433Term: Metabolism and nutrition disordersSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2021-005273-47-ATEli Lilly and Company140
进行中（未招募）
3 期
Patients with major Adverse Events With Type 2 DiabetesCTRI/2020/04/024938Eli Lilly and Company India Pvt Ltd